Eris Lifesciences share price
You have to be logged in to add this to Watchlist.- ₹1,783.50(-0.38%)June 13, 2025 15:29:35 PM IST
- NSE
- BSE
- Vol : 287.87K (NSE + BSE)Last 20 day avg : 384.00 K
Eris Lifesciences is trading -0.38% lower at Rs 1,783.50 as compared to its last closing price. Eris Lifesciences has been trading in the price range of 1,815.80 & 1,734.55. Eris Lifesciences has given 30.39% in this year & 8.43% in the last 5 days. Eris Lifesciences has TTM P/E ratio 54.75 as compared to the sector P/E of 24.72.There are 9 analysts who have initiated coverage on Eris Lifesciences. There are 5 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 93.84 Crores in its last quarter.Listed peers of Eris Lifesciences include J B Chemicals And Pharmaceutical (-1.44%), Wockhardt (-0.35%), Eris Lifesciences (-0.38%).The Mutual Fund holding in Eris Lifesciences was at 16.59% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Eris Lifesciences was at 8.43% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 13, 2025, 03:52 PM UTC
- Dividend YieldLower than industry0.41Annual dividends as a percentage of the stock price.
- P/B8.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values69.29Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.87The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 28.02% from Rs 705.30 crore to Rs 550.93 crore, year-on-year
- The company has grown its March quarter profit by 32.24% from Rs 70.96 crore to Rs 93.84 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,814.67
- R2
- 2,047.48
- R3
- 2,185.42
- S1
- 1,443.92
- S2
- 1,305.98
- S3
- 1,073.17
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| J B Chemicals And Pharmaceutical | Moderately Bullish | 1,720.00 | -1.44 | 26,749.56 | 40.13 | 7.56 | 0.73 | 0.19 |
| Wockhardt | Bullish | 1,777.45 | -0.35 | 28,879.83 | - | 5.76 | - | 30.00 |
| Eris Lifesciences | Bullish | 1,783.50 | -0.38 | 24,380.65 | 65.54 | 8.07 | 0.43 | 62.42 |
| Alembic Pharmaceuticals | Moderately Bullish | 997.65 | 0.70 | 19,661.45 | 33.72 | 3.72 | 1.12 | 0.90 |
| Jubilant Pharmova | Bullish | 1,094.15 | -2.78 | 17,395.08 | 34.17 | 2.9 | 0.44 | 38.19 |
- Pledged found - Promoter(s) have pledged 18.51% of shares.
- Pledging Flat - Promoter(s) pledging has not increased in last quarter.
- Promoter(s) holds a high stake in the company at 54.85%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.07 percentage points from previous quarter
- Mutual Funds holding has increased by 0.07 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-19 | Audited Results |
| 2025-02-07 | Interim Dividend |
| 2025-02-04 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| 2024-08-02 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE406M01024
- BSE Code540596
- NSE CodeERIS
Eris Lifesciences is trading at 1783.50 as on Fri Jun 13 2025 09:59:35. This is -0.38% lower as compared to its previous closing price of 1790.25.
The market capitalization of Eris Lifesciences is 24380.65 Cr as on Fri Jun 13 2025 09:59:35.
The average broker rating on Eris Lifesciences is Strong Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 3 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Eris Lifesciences is 1909.55 whereas the 52 wk low is 988.95
Eris Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 54.75
- Sector P/E: 24.72
- Dividend Yield: 0.41%
- D/E ratio: 0.87
Eris Lifesciences reported a net profit of 351.84 Cr in 2025.
The Mutual Fund Shareholding was 16.59% at the end of 31 Mar 2025.